{"id":7148,"date":"2011-04-06T13:39:00","date_gmt":"2011-04-06T13:39:00","guid":{"rendered":"https:\/\/www.adacyte.com\/?post_type=scientific-corner&p=7148"},"modified":"2022-04-01T13:47:05","modified_gmt":"2022-04-01T13:47:05","slug":"current-and-emerging-drugs-for-the-treatment-of-inflammatory-bowel-disease","status":"publish","type":"scientific-corner","link":"https:\/\/www.adacyte.com\/fr\/professional\/scientific-corner\/current-and-emerging-drugs-for-the-treatment-of-inflammatory-bowel-disease\/","title":{"rendered":"Current and emerging drugs for the treatment of inflammatory bowel disease"},"content":{"rendered":"
\n

John K Triantafillidis<\/a>,\u00a0Emmanuel Merikas<\/a>, and\u00a0Filippos Georgopoulos<\/a> Drug Des Devel Ther.<\/a>\u00a02011; 5: 185\u2013210.\u00a0doi:\u00a010.2147\/DDDT.S11290<\/a><\/p>\n<\/div>\n\n

\n

During the last decade a large number of biological agents against tumor necrosis factor-\u03b1 (TNF-\u03b1), as well as many biochemical substances and molecules specifically for the medical treatment of patients with inflammatory bowel disease (IBD), have been developed. This enormous progress was a consequence of the significant advances in biotechnology along with the increased knowledge of the underlying pathophysiological mechanisms involved in the pathogenesis of IBD. However, conventional therapies remain the cornerstone of treatment for most patients. During recent years conventional and biologic IBD therapies have been optimized. Newer mesalazine formulations with a reduced pill size and only one dose per day demonstrate similar efficacy to older formulations. New corticosteroids retain the efficacy of older corticosteroids while exhibiting a higher safety profile. The role of antibiotics and probiotics has been further clarified. Significant progress in understanding thiopurine metabolism has improved the effective dose along with adjunctive therapies. Quite a large number of substances and therapies, including biologic agents other than TNF-\u03b1 inhibitors, unfractionated or low-molecular-weight heparin, omega-3 polyunsaturated fatty acids, microbes and microbial products, leukocytapheresis, and other substances under investigation, could offer important benefits to our patients. In this paper we review the established and emerging therapeutic strategies in patients with Crohn\u2019s disease and ulcerative colitis.<\/p>\n<\/div>\n\n

\n

https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3084301\/<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

John K Triantafillidis,\u00a0Emmanuel Merikas, and\u00a0Filippos Georgopoulos Drug Des Devel Ther.\u00a02011; 5: 185\u2013210.\u00a0doi:\u00a010.2147\/DDDT.S11290 During the last decade a large number of biological agents against tumor necrosis factor-\u03b1 (TNF-\u03b1), as well as many biochemical substances and molecules specifically for the medical treatment of patients with inflammatory bowel disease (IBD), have been developed. This enormous progress was a […]<\/p>\n","protected":false},"template":"","scientific_tags":[424,474,228,465,74,512,173,53,156,406,183],"class_list":["post-7148","scientific-corner","type-scientific-corner","status-publish","hentry","scientific_tags-gma","scientific_tags-hgf","scientific_tags-il1r","scientific_tags-intensive","scientific_tags-leukocytapheresis","scientific_tags-leukocyte-infiltration","scientific_tags-moa","scientific_tags-refractory-patients","scientific_tags-safety","scientific_tags-stnf","scientific_tags-tnf-"],"acf":{"sc_authors":""},"yoast_head":"\nCurrent and emerging drugs for the treatment of inflammatory bowel disease - Adacyte<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/current-and-emerging-drugs-for-the-treatment-of-inflammatory-bowel-disease\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Current and emerging drugs for the treatment of inflammatory bowel disease - Adacyte\" \/>\n<meta property=\"og:description\" content=\"John K Triantafillidis,\u00a0Emmanuel Merikas, and\u00a0Filippos Georgopoulos Drug Des Devel Ther.\u00a02011; 5: 185\u2013210.\u00a0doi:\u00a010.2147\/DDDT.S11290 During the last decade a large number of biological agents against tumor necrosis factor-\u03b1 (TNF-\u03b1), as well as many biochemical substances and molecules specifically for the medical treatment of patients with inflammatory bowel disease (IBD), have been developed. This enormous progress was a […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/current-and-emerging-drugs-for-the-treatment-of-inflammatory-bowel-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"Adacyte\" \/>\n<meta property=\"article:modified_time\" content=\"2022-04-01T13:47:05+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/current-and-emerging-drugs-for-the-treatment-of-inflammatory-bowel-disease\/\",\"url\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/current-and-emerging-drugs-for-the-treatment-of-inflammatory-bowel-disease\/\",\"name\":\"Current and emerging drugs for the treatment of inflammatory bowel disease - Adacyte\",\"isPartOf\":{\"@id\":\"https:\/\/www.adacyte.com\/#website\"},\"datePublished\":\"2011-04-06T13:39:00+00:00\",\"dateModified\":\"2022-04-01T13:47:05+00:00\",\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/current-and-emerging-drugs-for-the-treatment-of-inflammatory-bowel-disease\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.adacyte.com\/#website\",\"url\":\"https:\/\/www.adacyte.com\/\",\"name\":\"Adacyte\",\"description\":\"Adacyte Therapeutics\",\"publisher\":{\"@id\":\"https:\/\/www.adacyte.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.adacyte.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.adacyte.com\/#organization\",\"name\":\"Adacyte\",\"url\":\"https:\/\/www.adacyte.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"contentUrl\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"width\":165,\"height\":46,\"caption\":\"Adacyte\"},\"image\":{\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Current and emerging drugs for the treatment of inflammatory bowel disease - Adacyte","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/current-and-emerging-drugs-for-the-treatment-of-inflammatory-bowel-disease\/","og_locale":"fr_FR","og_type":"article","og_title":"Current and emerging drugs for the treatment of inflammatory bowel disease - Adacyte","og_description":"John K Triantafillidis,\u00a0Emmanuel Merikas, and\u00a0Filippos Georgopoulos Drug Des Devel Ther.\u00a02011; 5: 185\u2013210.\u00a0doi:\u00a010.2147\/DDDT.S11290 During the last decade a large number of biological agents against tumor necrosis factor-\u03b1 (TNF-\u03b1), as well as many biochemical substances and molecules specifically for the medical treatment of patients with inflammatory bowel disease (IBD), have been developed. This enormous progress was a […]","og_url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/current-and-emerging-drugs-for-the-treatment-of-inflammatory-bowel-disease\/","og_site_name":"Adacyte","article_modified_time":"2022-04-01T13:47:05+00:00","twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/current-and-emerging-drugs-for-the-treatment-of-inflammatory-bowel-disease\/","url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/current-and-emerging-drugs-for-the-treatment-of-inflammatory-bowel-disease\/","name":"Current and emerging drugs for the treatment of inflammatory bowel disease - Adacyte","isPartOf":{"@id":"https:\/\/www.adacyte.com\/#website"},"datePublished":"2011-04-06T13:39:00+00:00","dateModified":"2022-04-01T13:47:05+00:00","inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.adacyte.com\/professional\/scientific-corner\/current-and-emerging-drugs-for-the-treatment-of-inflammatory-bowel-disease\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.adacyte.com\/#website","url":"https:\/\/www.adacyte.com\/","name":"Adacyte","description":"Adacyte Therapeutics","publisher":{"@id":"https:\/\/www.adacyte.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.adacyte.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.adacyte.com\/#organization","name":"Adacyte","url":"https:\/\/www.adacyte.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","contentUrl":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","width":165,"height":46,"caption":"Adacyte"},"image":{"@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/scientific-corner\/7148","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/scientific-corner"}],"about":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/types\/scientific-corner"}],"wp:attachment":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/media?parent=7148"}],"wp:term":[{"taxonomy":"scientific_tags","embeddable":true,"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/scientific_tags?post=7148"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}